Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05399992

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.

Official title: VICTORION REAL: An International Prospective Real-world Study to Evaluate the LDL-C changE and Adherence to incLisiran in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

OBSERVATIONAL

Enrollment

847

Start Date

2022-09-12

Completion Date

2026-10-05

Last Updated

2026-02-03

Healthy Volunteers

No

Interventions

OTHER

Inclisiran

Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.

Locations (40)

Novartis Investigative Site

Feldkirch, Austria

Novartis Investigative Site

Graz, Austria

Novartis Investigative Site

Linz, Austria

Novartis Investigative Site

Sankt Veit im Pongau, Austria

Novartis Investigative Site

Vienna, Austria

Novartis Investigative Site

Vienna, Austria

Novartis Investigative Site

Shenzhen, Guangdong, China

Novartis Investigative Site

Holon, Gush Dan, Israel

Novartis Investigative Site

Petah Tikva, Israel

Novartis Investigative Site

Tel Aviv, Israel

Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, Malaysia

Novartis Investigative Site

Kuala Lumpur, Malaysia

Novartis Investigative Site

Riyadh, Saudi, Saudi Arabia

Novartis Investigative Site

Jeddah, Saudi Arabia

Novartis Investigative Site

Tabuk, Saudi Arabia

Novartis Investigative Site

Fribourg, CH, Switzerland

Novartis Investigative Site

Basel, Switzerland

Novartis Investigative Site

Geneva, Switzerland

Novartis Investigative Site

Lausanne, Switzerland

Novartis Investigative Site

Olten, Switzerland

Novartis Investigative Site

Sankt Gallen, Switzerland

Novartis Investigative Site

Zurich, Switzerland

Novartis Investigative Site

Zurich, Switzerland

Novartis Investigative Site

Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

Novartis Investigative Site

Dubai, United Arab Emirates, United Arab Emirates

Novartis Investigative Site

Abu Dhabi, United Arab Emirates

Novartis Investigative Site

Al Ain City, United Arab Emirates

Novartis Investigative Site

Dubai, United Arab Emirates

Novartis Investigative Site

High Wycombe, Buckinghamshire, United Kingdom

Novartis Investigative Site

Louth, Lincolnshire, United Kingdom

Novartis Investigative Site

Sunderland, Tyne and Wear, United Kingdom

Novartis Investigative Site

Belfast, United Kingdom

Novartis Investigative Site

Bromwich, United Kingdom

Novartis Investigative Site

Burton-on-Trent, United Kingdom

Novartis Investigative Site

Cardiff, United Kingdom

Novartis Investigative Site

Hull, United Kingdom

Novartis Investigative Site

Lancaster, United Kingdom

Novartis Investigative Site

Liverpool, United Kingdom

Novartis Investigative Site

London, United Kingdom

Novartis Investigative Site

Middlesex, United Kingdom